Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2351-2360

  Yotsumoto, Fusanori ^a,b   Fukami, Tatsuya ^b,c   Yagi, Hiroshi ^d   Funakoshi, Akihiro ^e   Yoshizato, Toshiyuki ^c   Kuroki, Masahide ^a,b   Miyamoto, Shingo ^b,c  

^a School of Medicine   (Japan)

^b Center for Advanced Molecular Medicine   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; AMPHIREGULIN ANTIBODY; CETUXIMAB; CISPLATIN; DIPHTHERIA TOXOID CRM197; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HETERODIMER; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PROTEIN ANTIBODY; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NICK END LABELING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANTIBODIES; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOPROTEINS; HUMANS; IMMUNOBLOTTING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PACLITAXEL; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 78049437131     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01671.x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-57.
3. Burris HA III, Moore MJ, Andersen MJ et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
4. Moore MJ, Goldstein D, Hamm J et al. Erlotinib+gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2007; 25: 1960-6.
5. Welch SA, Moore MJ. Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag? J Clin Oncol 2007; 25: 2159-61.
6. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1: 989-97.
7. Simon PO Jr, McDunn JE, Kashiwagi H et al. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer 2009; 125: 942-51.
8. Frolov A, Schuller K, Tzeng CW et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 2007; 6: 548-54.
9. Sergina NV, Rausch M, Wang D et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-41.
10. Yotsumoto F, Yagi H, Suzuki SO et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 2008; 365: 555-61.
11. Shoyab M, McDonald VL, Bradley JG, Todaro GJ. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 1988; 85: 6528-32.
12. Sunnarborg SW, Hinkle CL, Stevenson M et al. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002; 277: 12838-45.
13. Berasain C, Garcia-Trevijano ER, Castillo J et al. Novel role for amphiregulin in protection from liver injury. J Biol Chem 2005; 280: 19012-20.
14. Berasain C, Garcia-Trevijano ER, Castillo J et al. Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology 2005; 128: 424-32.
15. Luetteke NC, Qiu TH, Fenton SE et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999; 126: 2739-50.
16. Troyer KL, Luetteke NC, Saxon ML, Qiu TH, Xian CJ, Lee DC. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-alpha. Gastroenterology 2001; 121: 68-78.
17. Wagner M, Greten FR, Weber CK et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of human disease. Genes Dev 2001; 15: 286-93.
18. Wagner M, Weber CK, Bressau F et al. Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells. Gastroenterology 2002; 122: 1898-912.
19. Ebert M, Yokoyama M, Kobrin MS et al. Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 1994; 54: 3959-62.
20. Yagi H, Yotsumoto F, Sonoda K et al. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 2009; 124: 1429-39.
21. Miyamoto S, Hirata M, Yamazaki A et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004; 64: 5720-7.
22. Shafer A, Zhou C, Paola A, Boggess JF, Bae-Jump VL. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer 2010; 126: 1144-54.
23. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7: 163-72.
24. Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancers. Cancer Invest 2003; 21: 887-96.
25. Burgess AW, Cho HS, Eigenbrot C et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors Mol Cell 2003; 12: 541-52.
26. Lemmon MA. Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009; 315: 638-48.
27. Weihua Z, Tsan R, Huang WC et al. Survival of Cancer cells in maintained by EGFR independent of its kinase activity. Cancer Cell 2008; 13: 385-93.
28. Chau I, Cunningham D, Russell C et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomized controlled trials. Br J Cancer 2006; 94: 1107-15.
29. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-7.
30. Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-55.